transform continu expect good thing ahead rate buy
baxter complet second year leadership ceo almeida
second full year follow separ baxalta almeida
strategi consist portfolio innov manag oper
excel capit alloc view baxter made progress
across area particularli oper excel look ahead
expect manag continu deliv across three vector though
net debt ebitda zero expect capit alloc play increasingli
import part baxter stori expect manag
execut well upgrad baxter buy versu prior hold rate price
target
guid appear achiev conserv target within reach
manag expect constant currenc oper sale growth
consist long-rang forecast oper margin
expect expand though sever one-tim factor aect
pace expans even factor manag still expect
margin improv help drive ep healthi
believ baxter goal within reach
see may analyst day upcom catalyst
may manag plan host analyst meet review pipelin
provid updat long-rang plan expect manag least
rearm target provid aspir believ baxter
approach inect point top line perspect expect
growth acceler higher given increas weight growth
area like gener inject improv area like in-cent hemodialysi
contribut new product contribut capit deploy
believ stock deserv premium valuat price target
believ premium multipl warrant sustain
expand compani continu transform faster top-lin
growth compani relentless focu protabl mix shift capit
alloc given balanc sheet strength cash ow prole
price feb usd
hold buy
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
detail later report baxter histori lled period
success also stumbl often lead vast restructur period spin-
os and/or divestitur manag change-ov believ baxter
transit enter period success baxter complet
second year leadership almeida second full year follow
separ baxalta blood plasma busi occur
almeida join baxter success tenur covidien/tyco healthcar
serv compani presid ceo prior
presid medic devic busi believ right
person lead compani transit importantli creat
right team around lead baxter next chapter compani one
believ success
strategi almeida consist three strateg vector portfolio
innov manag oper excel capit alloc
view compani made progress across three vector
portfolio manag innov manag upon join
baxter almeida along manag team embark
strateg review portfolio result strateg
realign compani baxter manag identi sever
core area growth includ gener inject nutrit acut
renal care biosurgeri posit compani end
compani discontinu home hemodialysi program
develop free dollar repurpos
program return expect higher baxter also
exit busi geographi prot margin
low near zero
oper excel regard baxter made
signic progress past two year baxter signicantli
improv oper margin balanc sheet cash ow metric
manag implement zero-bas budget disciplin
discretionari spend across busi geographi
end result -- baxter oper margin increas
ow continu oper total
billion billion free cash ow
billion million baxter end year net
debt ebitda zero
capit alloc view baxter still earli inning
capit alloc stori though made move
acquisit generic-inject manufactur clari last year
pend acquisit biosurgeri asset baxter also
enter partnership scinopharm dorizo lifesci
figur baxter adjust oper margin expans time
look ahead expect manag continu deliv across
three vector though net debt ebitda zero expect capit
alloc play increasingli import part baxter stori go forward
expect manag execut well one key success stori
covidien tuck-in acquisit almeida play integr part
view covidien good track record acquisit
term nding right asset pay appropri valuat asset
expect good thing ahead
guid appear achiev conserv target within reach
baxter issu guidanc earlier month believ achiev
conserv note past two year manag issu
guidanc exceed forecast believ could case
year well manag execut cost save
oper excel plan time competit cyclophosphamid
also one swing factor
manag expect constant currenc oper sale growth
consist long-rang forecast within forecast renal expect
acut therapi medic deliveri nutrit
advanc surgeri expect
year-over-year despit increment clari sale due impact
cyclophosphamid competit well dicult comparison one-tim
sale prior year foreign exchang expect add approxim
top line forecast
oper margin expect expand though sever
one-tim factors/headwind aect pace expans manag
comment cyclo headwind margin transit
servic agreement roll anoth foreign exchang around
even factor manag expect margin improv
drive ep healthi
model ep manag expect gener
oper free cash ow billion free cash ow billion
think target achiev model line forecast
last year manag upwardli revis margin ep nancial
target due out-performance oper excel initi
manag rais oper margin target
ep goal current model
margin though given acquisit clari out-performance
believ ep goal low current model
ep
see may analyst day upcom catalyst
may manag plan host analyst meet review pipelin
provid updat long-rang plan
expect manag highlight sever key area within portfolio name
core growth area gener inject acut renal therapi biosurgeri
nutrit also expect manag highlight key product
hdx therapi enabl theranova dialyz part
turnaround stori within renal care busi
gener inject baxter build capabl abl
better compet attract billion-plu gener inject
segment allow acceler overal sale
growth also improv margin prole well feburari
baxter enter strateg partnership scinopharm develop
manufactur commerci inject drug use rang
cancer treatment current brand sale product
billion agreement also allow option partner
scinopharm mani addit inject molecul
well term agreement baxter hold commerci
right product product expect launch
beyond june baxter enter agreement
dorizo lifeci allow acceler develop
gener inject product area anti-infect
oncolyt cardiovascular medicin term
agreement dorizo perform certain product develop activ
baxter hold world-wide manufactur commerci
right largest notabl transact acquisit
clari inject close juli total million
clari expect contribut million sale year
margin accret ebitda margin rang baxter
anticip launch product clari portfolio
expect increas pace product year beyond
mainli continu renal replac therapi crrt
mark new indic oxiri set sepsi manag
protocol repres new opportun growth
biosurgeri advanc surgeri busi histor
busi area suer underinvest
bioscienc segment baxter increas invest well
made target acquisit pend acquisit recothrom
preveleak bolster growth
nutrit baxter oer one broadest portfolio iv nutrit
therapi continu launch new product simultan
expand geograph footprint
turnaround renal baxter acquir
gambro busi
hemodialysi septemb view acquisit
under-perform look ahead believ theranova dialyz
new ak hemodialysi system help improv
perform busi global launch expand
hemodialysi hdx therapi enabl theranova dialyz kick
octob australia new zealand franc germani
switzerland belgium sinc baxter work
expand approv geographi well includ unit
state product current undergo clinic trial
clinic trial expect wrap year turn pave
way regulatori submiss approv may baxter
launch new version ak hemodialysi system oer
two-way connect capabl meet need patient
lower wright function simplifi treatment set reduc
downtim session system rst launch
avail asia europ latin america togeth
new dialyz new system along chang manag
help turn around perform busi
nancial perspect expect manag least rearm
oper margin target though believ ep guidanc rang like need
rais assum reinvest activ expect baxter provid
nancial long term aspir least believ baxter
inect point top line perspect look longer term
compani like see increas top line growth base level
higher given increas weight compani growth area
like gener inject improv area histor struggl like
in-cent hemodialysi new product contribut capit deploy
expect manag highlight continu opportun improv
margin vis-a-vi gross margin particular signic
improv cash gener improv cash gener
expect help fund compani next chapter -- one increas busi
develop opportun previous note baxter enviabl
zero net debt ebitda posit
believ stock deserv premium valuat
sinc spin-o baxalta share trade averag pe ntm
ep rel pe premium averag
repres premium compani within medic suppli
devic group howev believ premium multipl warrant
sustain expand given bottom line growth compani
continu transform faster top-lin growth compani
relentless focu protabl mix shift capit alloc also believ
premium warrant due balanc sheet strength improv cash ow
prole set price target use combin pe ev/ebitda
approach price target appli pe multipl ev/ebitda
multipl estim prior price target reli sole ev/
ebitda appli forward multipl
figur baxter split absolut rel pe ntm
downsid risk could impact ep forecast henc achiev
price target includ increas competit iv solut pd
therapi continu price pressure/competit in-cent dialysi
inabl complet transact lack margin improv across
busi lower uptak key new product launch fda/regulatori action
baxter histori mark period great success also period
signic challeng corpor restructur transit baxter
found intraven solut hospit product compani
subsequ expand oer blood collect dialysi
diagnost pharmaceut specialti space follow gure
display major compani mileston nearli past four decad
one favorit quot baxter annual report date march
could easili appli today time well william
chairman board vernon louck jr presid ceo
letter baxter sharehold write care deliveri around world
midst unpreced econom structur transform
contain eort nation govern health care payor
produc dramat shift way health care provid fund use
year comprehens public privat insur plan liber employe
benet program insul us actual health care cost mistakenli
often equat qualiti care quantiti price reward
ecienc provis health care louck refer
implement medicar inpati prospect payment system
use diagnosi relat group drg result price
environ hospit product come pressur reimburs
longer cost plu basi rather predetermin xed rate amount
later year baxter would make surpris oer one believ base
chang environ
june baxter launch billion take-over american hospit
suppli bid outstand oer tabl
acquisit notabl sinc hospit acquir medic suppli
distributor and/or medic devic equip manufactur seek
vertic integr acquir medic suppli distributor baxter ultim
acquir american hospit suppli howev acquisit go
plan put nice baxter went seri restructur round
baxter sold dade diagnost busi industri lifesci
divis ultim baxter decid essenti unwind american
suppli deal spin cost manag distribut busi
allegi allegi would ultim acquir cardin
baxter launch billion bid grace nation
medicar subsidiarya leader dialysi servic howev grace
manag team refus discuss bid sold busi freseniu
maker baxter continu seri acquisit period
includ unprot hemodialysi equip maker althin medic
north american vaccin baxter spun-o busi
continu acquisit spree includ
cook pharmaceut atsa medica onkologi lederl gener inject
busi well number deal focus bioscienc divis
music stoppedso-to-speakin compani sale
miss expect market becam awar signic amount
plasma product nearli ood market result reduct
price product categori turn set wave
challeng baxter compani sever round downward earn
revis turn stock fell even compani equiti
forward contract stock intent oset dilut employe
stock option plan pressur stock end
underwat billion late baxter decid exit major
renal servic busi baxter restructur shut
capac blood plasma marketsa
industri well consolid well collaps stock
baxter billion salesbaxt billion acquiredamerican hospit suppli acquiredcaremark acquiredimmuno intern mutlipl allegi edward multipl smaller acquisit licens deal gambro renal therapi servic rm diseas management -sale us gener inject hikma vaccin -acquiredclari inject dade diagnost unit bain capit industri lifesci divis vwr suppli distribut busi later acquir cardin februari
investor disappoint led departur then-ceo harri kraemer
much senior manag team
april baxter board director announc appoint robert
bob parkinson next chairman ceo parkinson extens career
thought one potenti next ceo
abbott howev parkinson appoint posit presid
ceo mile white parkinson depart month later go
academia time street hail parkinson right guy
right time lead baxter troubl experi within
medic deliveri hospit suppli busi
take ceo parkinson initi goal restor sharehold
credibl strengthen balanc sheet continu on-going eort
restructur compani improv qualiti earn eectiv
priorit initi creat new leadership team organiz
structur parkinson second phase launch focus
increas invest aggress pursu busi
develop opportun acceler growth year ahead
front baxter increas spend percent sale
though averag closer though view
success mix notabl disappoint
delay hyqvia failur alzheim trial late
develop extend half-lif factor viii product
busi develop side baxter acquisit one would
expect given commentari manag least initi
pace acquisit pick signicantli view becam
obviou bioscienc busi outlook could challeng
delay hyqvia late develop extend half-lif
factor viii largest deal acquisit gambro
billion acquisit licens collabor bolster
figur renal medic product acquisit
follow spin-o baxalta juli parkinson continu lead baxter
strategi parkinson optim core portfolio enhanc
protabl return expand capabl new product
busi develop view right strategi employ
market question whether could properli implement
given histori compani
octob baxter board director announc almeida join
compani execut would succeed parkinson chairman
ceo eectiv januari almedia join baxter success tenur
covidien/tyco healthcar serv compani presid ceo
prior presid medic devic busi
addit covidien also held leadership posit wilson greatbatch
technolog inc american product acufex microsurg divis
johnson johnson profession product divis believ right
anncmt dateeffect datetarget named valu db product recothrom market gener ab product portfolio consist primarili dialysi product acquisit strengthen baxter renal develop infus pump technolog includ spectrum larg volum pump lvp baxter aquir remain fasonut sanot disclosedlaboratoir fasonut sole produc parenter nutrit bag life biolog mechan product use soft tissu repair microsurgeri develop nexteron antiarrhythm product portfolio consist orthobiolog product product actifus silic substitu calcium phospahet synthet bone graft develop pharmaci technolog enhanc efficiency/safeti oral iv dose prepar deliveri annual sale lifesci crrt continu renal replac therapi crrt develop infus pump technolog includ spectrum larg volum pump lvp baxter aquir acquir lederl busi wyeth includ inject drug portfolio manufactur fluid busi includ manufactur asset facil medic acquisit baxter acquir floseal fusion product medica produc therapi product cancer compani lead product includ endoxan cyclophosphamid holoxan ifex ifosfamid uromitexan mesnex mesna solut provid complet line pharmaceut contract manufactur servic includ number steril product dosag form solut suspens freeze-dri lyophil powder varieti deliveri system includ vial pre-fil medic product februari
person lead compani transit importantli creat right
team around lead baxter next phase compani transit
strategi almeida dissimilar initi parkinson
consist three strateg vector portfolio innov manag
oper excel capit alloc view compani
made progress across three vector particularli oper
excel look ahead expect manag continu deliv
across three vector though net debt ebitda zero expect
capit alloc play increasingli import part baxter stori go
forward expect manag execut well one key success
stori covidien tuck-in acquisit almeida play integr
part view covidien good track record acquisit
term nding right asset pay appropri valuat
asset
today baxter global medic suppli devic compani oper
countri physic presenc compani sale
total billion compani compet across seven sub-seg
view two broader bucket renal renal acut therapi
surgeri
figur sale global busi
figur sale region latest break-out
expect exceed
baxter renal busi unit gener million sale
repres total compani sale sale year-
over-year basi consist patient growth driven mid-singl digit growth
within pd segment busi includ product servic treat end
stage renal diseas esrd includ periton dialysi pd well in-cent
chronic renal failur end stage renal diseas esrd estim impact
approxim million patient world-wide age popul
grow preval risk factor kidney diseas diabet
adult diabet hypertens adult hypertens
cultur factor baxter expect preval patient chronic renal
failur grow compound-annual-growth-rate
periton dialysi pd use patient periton membran abdomin line
dialysi solut lter wast bloodstream oppos
extern dialyz case hemodialysi gener treatment manag
patient home one two method infus exchang
pd solut rst continu ambulatori periton dialysi capd
solut lter cathet sever time day via graviti second
autom periton dialysi solut pump automat
cycler machin usual night
baxter two main product within pd segment amia us market
claria ou pd cycler amia homechoic claria includ
platform allow physician view statu patient pd treatment remot
physician review home dialysi treatment data adjust patient home
devic set without patient come clinic set expect baxter
launch kaguya system japan driver
addit growth within pd segment note japan second
highest preval per million popul treat esrd behind taiwan
ahead unit state
hemodialysi hd life save treatment wherebi patient blood typic
remov arm pump extern dialyz
ltere return bodi per unit state renal data system
usrd preval esrd patient receiv hd among
dialysi case use in-cent hd versu use home hd
outsid us particularli europ percentag in-cent hd tend
lower
in-cent hemodialysi in-cent hd requir patient travel dialysi
center receiv dialysi treatment three time per week
hemodialysi perform patient home perform
day patient asleep baxter compet in-cent
space discontinu develop home dialysi program
primari product in-cent hemodialysi market includ dialyz
hemodialysi machin though market also includ concentr
dialysi solut dialyz compris largest percentag market
estim global sale volum million unit versu
approxim hemodialysi machin baxter sell sever dialyz
in-cent hemodialysi system well associ dispos ancillari
may baxter launch new version ak hemodialysi system
oer two-way connect capabl meet need patient
lower wright function simplifi treatment set reduc downtim
session system rst launch current
avail asia europ latin america baxter work bring system
market unit state
opportun theranova
octob baxter launch expand hemodialysi hdx therapi
enabl theranova dialyz australia new zealand franc germani
switzerland belgium
theranova hdx technolog simpli remov larger molecul
associ mortal chronic kidney diseas eectiv
provid outcom better hemodialtr hdf use regular
special water ltration system requir special sta
compat monitor produc compani baxter expect
expans clinic evid parallel launch current
technolog market kind well receiv western
europ australia product current clinic trial us
would expect fda approv theranova sometim
therapi crrt organ support therapi focus intens care
unit icu total sale million repres total sale
sale year-over-year basi baxter largest player
approxim billion acut therapi market approxim
continu renal replac therapi crrt allow toler uid
remov primarili indic unstabl patient
uid overload shock use patient acut kidney injuri aki
occur hour day rather chronic kidney diseas
benet crrt therapi current underutil patient
acut kidney injuri due lack market awar current
crrt patient world-wide howev baxter estim addit
individu treat crrt diagnos correctli
increas crrt therapi adopt could provid much million market
opportun via convers intermitt hd
baxter estim share crrt market japanes compani
nikkiso though freseniu also small presenc baxter view crrt
busi high margin busi believ opportun
grow market share posit leverag exist baxter sale channel
core compet
acut therapi segment baxter also record sale therapeut
plasma exchang tpe busi though busi current nomin
relat crrt treat number autoimmun diseas well liver
support drug poison therapi revenu compani note see
opportun increas market opportun million
addit lung support well sever sepsi manag capabl
current icu oer
septemb baxter announc commerci launch new indic
oxiri set sepsi manag protocol remov excess
level cytokin endotoxin inammatori mediat patient
blood baxter receiv ce mark regulatori approv label expans
plan le expand indic addit countri
administr set drug reconstitut devic sale total
million total compani sale sale year-over-year
infus devic within segment product servic
includ larg volum pump high margin dispos elastometr
drug deliveri devic main line pump compani sell
spectrum pump acquir compani
prior pump famili colleagu legaci fda problem
ultim remov us market remain region
outsid unit state baxter plan introduc updat
spectrum pump us later year baxter estim current
hold market share unit state main competitor
includ
administr set includ segment product servic
administr vascular set well broad portfolio
needleless access product product design reduc
hospit acquir infect main competitor includ
iv solut therapi segment rang basic specialti
solut small larg volum steril solut baxter focus
iv solut meet clinic need incorpor essenti lifesav
product year baxter benet abil import solut
mexico facil unit state help address
shortag million increment opportun
compani competitor space includ braun
pharmaceut includ compani premix oncolog drug platform
inhal anesthesia critic care product pharmaci compound
servic sale total million repres total compani
sale sale benet increment sale clari
acquisit took place juli one-tim earli contract settlement
though oset neg impact hurrican maria
premix oncolog drug
gener premix oncolog inject compris one fastest grow
categori within baxter strateg object segment includ expand
core premix gener oncolog molecul enter near
core busi gener inject includ ready-to-us rtu bag vial
reconstitut devic baxter expand new premix oncolog
product organ inorgan baxter intend grow product
portfolio align custom need ad scale strength
within channel compani intend launch addit new
molecul us manag believ
repres peak sale opportun excess million
histor cyclophosphamid
cyclophosphamid cyclo oncolog medic use chemotherapi
also number diseas state cyclophosphamid gener
around million sale contribut nearli per share earn
novemb sandoz freseniu receiv fda approv gener version
drug sinc sale attribut cyclophosphamid fallen
million million million baxter
current expect sale million though time competit
entri proven dicult predict
baxter enter attract partnership inject
baxter enter strateg partnership scinopharm februari
develop manufactur commerci inject drug use rang
cancer treatment current brand sale product billion
agreement also allow option partner scinopharm mani
addit inject molecul well term agreement
baxter hold commerci right product product
expect launch beyond view partnership like
focu investor day may product could start
driver period
june baxter enter agreement dorizo lifeci allow
acceler develop gener inject product
area anti-infect oncolyt cardiovascular medicin
term agreement dorizo perform certain product develop
activ baxter hold world-wide manufactur commerci
right view baxter build capabl abl better
compet attract billion-plu gener inject segment
allow acceler overal growth
figur clari product
juli baxter acquir clari inject total million clari
gener million sale expect gener sale
million clari margin accret ebitda margin
rang clari therapeut focu three core area anesthesia
analges anti-infect critic care renal time
acquisit announc decemb clari us approv product
us anda await approv also registr
eu regul countri registr emerg
market baxter anticip launch product expect
increas pace product year beyond
baxter lead manufactur inhal anesthesia long histori
space compani rst oer common modern
inhal anesthet current oer anesthet gase inhal anesthet
anesthesia-rel critic care drug product segment includ
supran sevouran foran lsouran
peri-op
periop segment includ servic product use enhanc
surgic safeti ecienc product includ brevibloc fast-act iv
beta blocker transderm scop anti-nausea patch specialti surgic
product also categori critic care product
brevibloc intraop post-op product control hypertens
may occur atrial brillat actifus bone graft substitut
acceler bone format
nutrit sale includ compani parenter nutrit pn therapi
sale total million repres total compani sale sale
year-over-year basi
baxter began provid nutrit therapi introduct
liquid protein form amino acid sinc baxter advanc
nutrit portfolio continu improv nutrit content
current baxter oer one broadest portfolio iv nutrit therapi
oliv lipid amino acid compound outsourc compound
compani estim nutrit market repres signic growth
opportun intend optim global portfolio via geograph expans
product enhanc also expand broader market
advanc surgeri includ biolog product medic devic use
surgic procedur hemostasi tissu seal adhes prevent
product within advanc surgeri includ floseal tisseel hemostat
agent sale total million repres total compani
sale sale year-over-year basi
januari baxter announc acquisit two hemostat
sealant product front payment
million potenti conting payment approxim million baxter
preveleak surgic sealant two product combin sale
million last twelv month end septemb deal
expect modestli accret
recothrom topic thrombin indic aid hemostasi
whenev ooz blood minor bleed capillari small
venul access control bleed standard surgic
techniqu sutur ligatur cauteri ineect
impract adult pediatr popul greater equal
one month age
vascular
reconstruct achiev adjunct hemostasi mechan
seal area leakag
indic use
sale includ compani pharmaceut partner busi
sale total million repres total compani sale
sale segment expect grow low single-digit rang
gener low margin natur
takeawaysvari analysi surpris histori exceptp share product sale trend milrptdex-fxren revenu expect grow report basi constant currenc basi sale expect flat oper ep guidanc full year revenu expect increas report basi constant currenc oper full year ep guidanc million line factset fs sale report basi constant currenc basi y/i growth driven strength acut therapi ep y/i ahead fs adjust gross margin declin y/i adjust oper margin y/i addit detail quarter million except per share data chang sale constant currenc basi unless otherwis sale ep ahead street expect changemix expansionquick total sale constant currenc basi oper initi off-set impact lost sale hurrican maria neg adj sg margin y/i adj margin y/i hurrican net interest expens increas prior adj tax rate reflect benefit stock compens adjust ep y/i ahead fs
figur baxter abbrevi incom statement million except per share data
baxtertot control net net incom adj operationsreconcili adjust epsamort net adjust februari
